A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
Condition: Non-Small Cell Lung Cancer
MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Intervention: bevacizumab; sunitinib; carboplatin; paclitaxel
Intervention description: Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle; 25 mg/day for 2 weeks, followed by 1 week of rest; On the first day of each cycle for 4 cycles; On the first day of each cycle for 4 cycles
Intervention MeSH terms: Paclitaxel; Bevacizumab; Carboplatin; Sunitinib
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 56.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: SABER-L; NSCLC; Avastin; Sutent

Summary:

      This is a Phase II, randomized, controlled, open-label, multicenter trial designed to provide
      a preliminary assessment of the safety and efficacy of sunitinib when combined with
      carboplatin and paclitaxel chemotherapy and bevacizumab in patients with locally advanced,
      recurrent or metastatic NSCLC who have not received prior systemic therapy for NSCLC. All
      patients will have advanced, histologically or cytologically confirmed NSCLC (Stage IIIb with
      pleural effusions, Stage IV, or recurrent).
    

Eligibility criteria:

        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Age ≥ 18 years

          -  Advanced histologically or cytologically confirmed NSCLC (Stage IIIb with malignant
             pleural or pericardial effusion, Stage IV, or recurrent)

          -  Measurable or non-measurable disease

          -  Patients with treated brain metastases are eligible if there is no evidence of
             progression or hemorrhage after treatment, as ascertained by clinical examination and
             brain imaging (MRI or CT) during the screening period (brain imaging to be competed
             Day -7 to Day 1).

          -  Prior treatment for CNS disease as deemed appropriate by the treating physician

          -  ECOG performance status 0 or 1

          -  Ability and willingness to comply with study and follow-up procedures

        Exclusion Criteria:

          -  Prior systemic chemotherapy for metastatic disease

          -  Active malignancy other than lung cancer

          -  Current, recent, or planned participation in another experimental drug study

          -  Prior treatment with anti-VEGF agent or agents targeting similar pathways as sunitinib

          -  Adjuvant chemotherapy or prior combined modality neoadjuvant therapy (chemotherapy
             plus radiotherapy with or without surgery) within 6 months prior to Day 1 of Cycle 1

          -  Life expectancy of < 12 weeks

          -  Current, recent, or planned participation in an experimental drug study

          -  Inability to take oral medication or requirement of IV alimentation or total
             parenteral nutrition, or prior surgical procedures affecting absorption

          -  Inadequate organ function

          -  Known evidence of disseminated intravascular coagulopathy

          -  Active infection or fever > 38.5°C within 3 days prior to Day 1 of Cycle 1

          -  Untreated abnormal thyroid function tests as defined by institutional standards
             (patients with controlled hypothyroidism are eligible for study participation)

          -  Any other medical condition(s) (including mental illness or substance abuse) deemed by
             the clinician to be likely to interfere with a patient's ability to provide informed
             consent, cooperate, or participate in the study, or to interfere with the
             interpretation of the results

          -  Intrathoracic lung carcinoma of squamous cell histology

          -  Known CNS disease except for treated brain metastases

          -  Inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association (NYHA) Class II or greater CHF

          -  History of myocardial infarction or unstable angina within 12 months prior to Day 1 of
             Cycle 1

          -  History of stroke or transient ischemic attack within 12 months prior to Day 1 of
             Cycle 1

          -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent
             peripheral arterial thrombosis within 6 months prior to Day 1 of Cycle 1

          -  History of hemoptysis within 1 month prior to Day 1 of Cycle 1

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation)

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1 of Cycle 1 or anticipation of need for major surgical procedure during
             the course of the study

          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to Day 1 of Cycle 1

          -  History of abdominal fistula or gastrointestinal perforation within 6 months prior to
             Day 1 of Cycle 1

          -  Serious, non-healing wound, active ulcer, or untreated bone fracture

          -  Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0
             at screening

          -  Known hypersensitivity to any component of bevacizumab or sunitinib

          -  Pregnancy (positive pregnancy test) or lactation